Samaritan Licenses Tumor Inhibiting Cancer Drugs That Also Distinguish Cancerous Tumors to Improve On Chemotherapy

Las Vegas, Nevada (PressExposure) April 10, 2008 -- Samaritan Pharmaceuticals, Inc. (OTC BB:SPHC.OB - website), a developer of innovative drugs, announced today that it has entered into an exclusive licensing agreement with Georgetown University for a patent covering the Peripheral Benzodiazepine Receptor (PBR) which has led to Cancer drug candidates with the ability to inhibit cancerous tumors; and an imaging technique that could possibly distinguish cancerous tumors for a more targeted and improved chemotherapy.

The patent entitled "Etoposide Conjugates with PBR Ligands" describes PBR as a high affinity drug and cholesterol-binding protein that has become an attractive target for cancer therapies and cancer imaging. Over-expression of PBR has been observed in a variety of cancers, including brain, breast, colorectal and prostate cancers.

See peer reviewed journal publications: []

Samaritan Pharmaceuticals: ``Transforming Today's Science Into Tomorrow's Cures...'' Samaritan Pharmaceuticals is a life science company focused on commercializing innovative drugs to relieve the suffering of patients with Alzheimer's, cancer, heart disease, and infectious disease. Samaritan's business strategy is to partner its later stage drugs after Phase II (proof of concept) human studies and has executed its first partnership for its PII, HIV drug SP-01A, with Pharmaplaz, Ireland. The FDA has authorized an investigational new drug (IND) # and a Phase I for its Alzheimer's drug Caprospinol and Samaritan has several other drugs it is advancing to enter (IND) status. In addition, Samaritan's sales arm has acquired the marketing and sales rights to sell ten revenue-generating products in Greece and various Eastern European countries.

Website: []. Please register so we can notify you of upcoming conference calls, news and events.

Disclaimer: The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings, and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science, and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 13, 2007. The company undertakes no duty to update forward-looking statements.

Contact: The Investor Relations Group Investor Relations: Adam Holdsworth Erica Ruderman Rachel Colgate 212-825-3210

About Samaritan Pharmaceuticals, Inc.

Samaritan Pharmaceuticals, Inc.
101 Convention Center Drive, Suite 310
Las Vegas, NV 89109

Press Release Source:,_Inc..html

Press Release Submitted On: February 12, 2008 at 5:42 pm
This article has been viewed 19143 time(s).